Am J Psychiatry 159:1793-1794, October 2002
© 2002 American Psychiatric Association
Sibutramine and Panic Attacks
KAREN BINKLEY, M.D., F.R.C.P.C., and
SANDRA R. KNOWLES, B.SC.PHM.
Toronto, Ont., Canada
To the editor: Sibutramine, a nonamphetamine appetite suppressant, is a selective norepinephrine, serotonin, and—to a lesser extent—dopamine reuptake inhibitor (1). There have been previous reports of psychosis (2), depression, mood changes, palpitations, and chest tightness associated with sibutramine, and hypomania has been linked to the combination of sibutramine and citalopram (3). However, to our knowledge, there have been no reported exacerbations of panic attacks. We report on a patient who had a history of panic attacks and experienced a recurrence of panic symptoms shortly after starting sibutramine.
Ms. A, a 62-year-old woman, had been diagnosed as having panic attacks during her mid-20s and had been initially treated with anxiolytics. She had been panic-free without treatment since her mid-30s, except for two attacks, both of which had occurred after minor surgical procedures.
Ms. A started taking sibutramine, 10 mg/day, for weight loss. After 1 weeks of taking sibutramine, she had two panic attacks in rapid succession. She discontinued the medication for several days and had no further attacks. She then restarted sibutramine and had another panic attack within approximately 3 days. She again discontinued sibutramine and has been asymptomatic for 5 months. Ms. A declined a third exposure to sibutramine. She was not unduly apprehensive about taking medication, and there were no obvious psychological stressors present at the time.
While it is not possible to definitively prove a causal relationship between sibutramine and panic attacks, the temporal relationship of the onset and disappearance of the panic attacks to the initiation and discontinuation of sibutramine is suggestive. With the Naranjo Adverse Drug Reactions Probability Scale (4), a high-probability relationship between sibutramine and the panic attacks was demonstrated in our patient. Although the mechanism for this reaction is unknown, physicians prescribing sibutramine should be aware of this potentially important side effect.
References
- McNeely W, Goa KL: Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56:1093-1124[CrossRef][Medline]
- Taflinski T, Chojnacka J: Sibutramine-associated psychotic episode (letter). Am J Psychiatry 2000; 157:2057-2058[Free Full Text]
- Benazzi F: Organic hypomania secondary to sibutramine-citalopram interaction (letter). J Clin Psychiatry 2002; 63:165[Medline]
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245[Medline]
This article has been cited by other articles:
|
|
|
|
 
P. Fernandez and A. Peiro
A Sibutramine-Induced Delusional Disorder Relapse
J Neuropsychiatry Clin Neurosci,
February 1, 2007;
19(1):
88 - 89.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. L. Petrakis, C. Nich, and E. Ralevski
Psychotic Spectrum Disorders and Alcohol Abuse: A Review of Pharmacotherapeutic Strategies and a Report on the Effectiveness of Naltrexone and Disulfiram
Schizophr Bull,
October 1, 2006;
32(4):
644 - 654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C Stoner, J. W Lea, A. L Wolf, and A. A Berges
Levetiracetam for Mood Stabilization and Maintenance of Seizure Control Following Multiple Treatment Failures
Ann. Pharmacother.,
November 1, 2005;
39(11):
1928 - 1931.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
